“we think we'll have that fully enrolled and reading out late in 2027”
→ Read the source episode
Avalon Pharma publicly announces Phase 2 clinical trial data for APO2 program
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.